About Us

Biography - Timothy Wiegand, MD, FACMT, FAACT, DFASAM

WiegandTimothy-www

Timothy J. Wiegand, MD, FACMT, FAACT, FASAM specializes in Medical Toxicology and Addiction Medicine. He is an Associate Professor of Emergency Medicine and the Director of Toxicology at Strong Memorial Hospital and for UR Medicine. Dr. Wiegand is also the Medical Director of Huther Doyle, an addiction services provider in Rochester, New York, where he works in a collaborative model providing a variety of services for patients with substance use disorders and serves as facilitator for their Project ECHO program on pain, opioid prescribing and addiction. In addition to ED, hospital and clinic work treating drug exposure, intoxication and withdrawal Dr. Wiegand is involved with medical education and research in toxicology and addiction. He is the Associate Program Director for the UR Medicine Combined Addiction Medicine Fellowship, which graduated their first Fellowship-trained Addiction Medicine physician this past July and he is core faculty for the Emergency Medicine residency at Strong Memorial Hospital. He lectures locally, regionally and nationally on topics in addiction medicine and medical toxicology and serves on the Board of Directors for several state and national organizations including the American College of Medical Toxicology, the Medical Toxicology Foundation and of the New York Society of Addiction Medicine. Dr. Wiegand is particularly interested in education in addiction medicine and the integration and collaboration between addiction medicine and medical toxicology. To this end he has served on the Addiction Medicine Committee for the American College of Medical Toxicology and coordinated several presentations from toxicologists at the annual scientific meeting for ASAM as well as for his state chapter, NYSAM. He has been awarded the Millennium Labs Late Breaking Abstract Research Award twice with submissions on A.) Addiction medicine training in medical toxicology fellowship programs and B.) the interpretation of buprenorphine metabolite levels in urine drug testing.

Disclosure of Interests and Affiliations